EU revokes marketing authorization for generic versions of Biogen's sclerosis drug
The European Commission has revoked marketing authorizations for generic versions of Biogen’s multiple sclerosis (MS) drug, Tecfidera, reports news agency Reuters.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.